ArticleJTCVS open2025
Surgical management of both stage III and stage IV pulmonary carcinoid tumors confers survival benefit.
Article in JTCVS open, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: Pulmonary carcinoid tumors are an uncommon entity, with an incidence of 1.35 cases per 100,000 individuals. Although decisions about surgical resection are commonly made similarly to those for non-small cell lung cancer, data surrounding the optimal treatment and prognostication for patients with advanced disease are limited. Thus, we sought to examine patterns of treatment, risk factors, and outcomes for advanced-stage pulmonary carcinoid tumors. Methods: We retrospectively reviewed healthcare system-wide data from an ongoing, prospectively followed primary lung cancer cohort to identify patients with stage III and IV pulmonary carcinoid tumors from 1997 to 2016, followed through 2023, and analyzed using multivariable Cox modeling and Kaplan-Meier estimates. Results: We identified 155 patients diagnosed with advanced-stage pulmonary carcinoid tumors (73 with stage III, 82 with stage IV). In patients with stage III, atypical histology (hazard ratio [HR], 2.91; 95% CI, 1.55-5.47; Conclusions: Advanced-stage pulmonary carcinoid tumors are a rare entity, infrequently described in the literature. Through a large retrospective analysis spanning 26 years, we have identified risk factors associated with mortality for advanced-stage pulmonary carcinoid tumors and demonstrated a potential role for surgical therapy in stage IV disease.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.